Advertisement

Clinical Rheumatology

, Volume 14, Issue 2, pp 187–190 | Cite as

Treatment of vasculitic leg ulcers in connective tissue disease with Iloprost

  • D. J. Veale
  • A. H. Muir
  • K. D. Morley
  • J. J. F. Belch
Originals

Summary

Leg ulcers are a recognised manifestation of cutaneous vasculitis in connective tissue diseases (CTDs) including rheumatoid arthritis (RA). Iloprost a stable prostacyclin analogue has been sucessfully used to treat Raynaud's phenomenon and digital ulcers associated with CTD's. Our aim was to assess iloprost in the treatment of vasculitic leg ulcers in CTD. In this paper we describe eight cases of vasculitic leg ulceration in association with RA and CTD, treated with intravenous iloprost. The iloprost was administered for 6–8 hours daily and continued for 21–28 days. Immunosuppressive therapy was required in three patients with severe necrotising vasculitis (RAnv). Complete ulcer healing was achieved in four patients within 6 weeks of commencing therapy while rapid improvement occurred in the other four patients. This suggests that iloprost may be useful as an adjunct to therapy for vasculitic leg ulcers. A double-blind placebo controlled study of iloprost therapy for RA leg ulcers is under way.

Key words

Vasculitis Leg Ulcers Iloprost 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Wilkinson, M., Kirk, J. Leg ulcers complicating rheumatoid arthritis. Scott Med J 1965, 10, 175–182.PubMedGoogle Scholar
  2. 2.
    Belch, J.J.F., Drury, J.K., Capell, H. et al. Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome — a double-blind controlled trial. Lancet 1983, 8320, 313–315.Google Scholar
  3. 3.
    Yardumian, D.A., Isenberg, D.A., Rustin, M. et al. Suecessful treatment of Raynaud's syndrome with iloprost, a chemically stable prostacyclin analogue. Br J Rheumatol 1988, 27, 222–226.Google Scholar
  4. 4.
    McHugh, N.J., Scuka, M., Watson, H. et al. Infusion of iloprost, a prostacyclin analogue, for the treatment of raynaud's phenomenon in systemic sclerosis. Ann Rheum Dis 1988, 47, 43–47.PubMedGoogle Scholar
  5. 5.
    Arnett, F.C., Edworthy, S., Block, D.A. et al. The 1987 revised ARA criteria for rheumatoid arthritis. Arthritis Rheum 1987, 30, S17.Google Scholar
  6. 6.
    Belch, J.J.F., Sanibadi, A., Dickson, R., Sturrock, R.D., Forbes, C.D. Effect of iloprost (ZK 36374) on white cell behavior. In: Prostacyclin and its Stable Analogue Iloprost. Eds.: Gryglewski, R.J., Stock, G. Springer Verlag, Berlin 1987, 97–102.Google Scholar

Copyright information

© Acta Medica Belgica 1995

Authors and Affiliations

  • D. J. Veale
    • 1
    • 2
  • A. H. Muir
    • 1
    • 2
  • K. D. Morley
    • 1
    • 2
  • J. J. F. Belch
    • 1
    • 2
  1. 1.University Department of MedicineDundee Medical School and Ninewells HospitalDundeeU.K.
  2. 2.Department of RheumatologyDundee Medical School and Ninewells HospitalDundeeU.K.

Personalised recommendations